PeerVoice Internal Medicine Audio
by PeerVoice
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇸🇦SA · Science#160500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 Weekly cadence·295 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇸🇦100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 14 epsHosts
Not detected.
Recent guests
Recent episodes
Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers
Sep 4, 2026
Unknown duration
Chongbo Zhao, MD - 探索不断变化的 CIDP 治疗格局：专家视角下的补体抑制疗法治疗潜力
Sep 4, 2026
Unknown duration
Laure Gossec, MD, PhD - Why Go Head-to-Head? How Comparative Trials Shape Today’s PsA Treatment Landscape - and Tomorrow’s
Sep 4, 2026
Unknown duration
Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices
Aug 27, 2026
Unknown duration
Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN
Aug 27, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 9/4/26 | Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers | Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers | — | ||||||
| 9/4/26 | Chongbo Zhao, MD - 探索不断变化的 CIDP 治疗格局：专家视角下的补体抑制疗法治疗潜力 | Chongbo Zhao, MD - 探索不断变化的 CIDP 治疗格局：专家视角下的补体抑制疗法治疗潜力 | — | ||||||
| 9/4/26 | Laure Gossec, MD, PhD - Why Go Head-to-Head? How Comparative Trials Shape Today’s PsA Treatment Landscape - and Tomorrow’s | Laure Gossec, MD, PhD - Why Go Head-to-Head? How Comparative Trials Shape Today’s PsA Treatment Landscape - and Tomorrow’s | — | ||||||
| 8/27/26 | Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices | Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices | — | ||||||
| 8/27/26 | Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN | Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN | — | ||||||
| 8/14/26 | Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement | Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement | — | ||||||
| 8/14/26 | Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes | Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes | — | ||||||
| 8/7/26 | Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes | Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes | — | ||||||
| 7/29/26 | Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies | Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies | — | ||||||
| 7/20/26 | kidney transplantmedical breakthroughs+3 | John Friedewald, MD, FASN, FAST | — | — | kidney transplantmedical breakthroughs+3 | — | 17m 39s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/20/26 | Acute Hepatic PorphyriaClinical Presentations+3 | — | One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings | — | Acute Hepatic Porphyriaclinical presentations+3 | — | 26m 33s | ||
| 7/20/26 | Atherosclerotic Cardiovascular DiseaseDisease Management+3 | Kausik Ray, MD, MPhil (Cantab), FMedSci | — | — | atherosclerosiscardiovascular disease+3 | — | 16m 39s | ||
| 6/29/26 | weight managementheart health+3 | Carel le Roux, MBChB, MSc, PhD | — | — | weight managementBMI+4 | — | 1h 17m 14s | ||
| 6/9/26 | metabolic diseaseMASH Matters+3 | Hannele Yki-Järvinen, MD, FRCPHannele Yki-Järvinen | — | — | MASH Mattersmetabolic disease+3 | — | 25m 41s | ||
| 6/9/26 | bladder cancermultidisciplinary team+3 | Andrea Necchi, MD | — | — | bladder cancerCME+3 | — | 21m 06s | ||
| 6/5/26 | TROP2-Directed ADCsAdvanced Breast Cancer+3 | Javier Cortés, MD, PhDLaura Huppert, MD | PeerVoice | — | TROP2ADCs+3 | — | 19m 41s | ||
| 6/5/26 | Rapid ARTGuidelines+3 | David Alain Wohl, MD | — | — | Rapid ARTHIV+3 | — | 20m 43s | ||
| 5/26/26 | stroke preventionmedical evidence+3 | Georgios Tsivgoulis, MD, PhD, MSc | — | — | strokeprevention+4 | — | 20m 17s | ||
| 5/26/26 | head and neck cancerrecurrent cancer+4 | Trisha Wise-Draper, MD, PhD | — | — | head and neck cancerrecurrent cancer+5 | — | 54m 23s | ||
| 5/18/26 | Folate Receptor-AlphaGynecological Cancers+3 | Martin Köbel, MD | — | — | Folate Receptor-Alphagynecological cancers+3 | — | 29m 59s | ||
| 5/18/26 | MASHFibrosis+3 | Sven Francque, MD, PhD | — | — | MASHFibrosis+3 | — | 35m 42s | ||
| 5/18/26 | Hypertrophic CardiomyopathyCardiac Myosin Inhibition+3 | Anjali Tiku Owens, MD | — | — | Hypertrophic CardiomyopathyCardiac Myosin Inhibition+3 | — | 1h 20m 09s | ||
| 4/29/26 | immunomodulationtype 1 diabetes+3 | Colin M. Dayan, MA, MBBS, FRCP, PhD | — | — | immunomodulationtype 1 diabetes+3 | — | 1h 19m 25s | ||
| 4/29/26 | Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can | Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can | — | ||||||
| 4/29/26 | Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy | Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy | — | ||||||
Showing 25 of 320
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for PeerVoice Internal Medicine Audio
Peaked at #160 in SA, currently #160 in SA.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SA | — | #160 | #160 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.